Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION

(CELG)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

CELGENE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Celgene Corporation - CELG

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 05:49pm EDT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Celgene Corporation (“Celgene”) (NasdaqGS: CELG) to Bristol-Myers Squibb Company (“Bristol-Myers”) (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Celgene will receive only $50.00 in cash and 1.0 shares of Bristol-Myers for each share of Celgene that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-celg/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
04/16CELGENE : Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb
AQ
04/15BRISTOL MYERS SQUIBB : Shareholders Approve Celgene Acquisition
AQ
04/15CELGENE : Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb
AQ
04/15BRISTOL MYERS SQUIBB : Celgene Deal Clears A Hurdle
DJ
04/12CELGENE CORP /DE/ : Submission of Matters to a Vote of Security Holders, Other E..
AQ
04/12BRISTOL MYERS SQUIBB : Myers says shareholders vote to approve Celgene takeover
RE
04/12BRISTOL MYERS SQUIBB : Myers Shareholders Approve $74 Billion Deal For Celgene -..
DJ
04/12BRISTOL MYERS SQUIBB : Myers Shareholders Approve $74 Billion Deal For Celgene
DJ
04/12BRISTOL MYERS SQUIBB : Myers Shareholders Vote in Favor of $74 Billion Celgene A..
DJ
04/12CELGENE : Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb
BU
More news
Financials ($)
Sales 2019 17 113 M
EBIT 2019 9 838 M
Net income 2019 6 141 M
Debt 2019 7 342 M
Yield 2019 -
P/E ratio 2019 10,75
P/E ratio 2020 8,91
EV / Sales 2019 4,28x
EV / Sales 2020 3,53x
Capitalization 65 862 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 96,8 $
Spread / Average Target 3,3%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION46.29%65 862
JOHNSON & JOHNSON6.56%366 184
ROCHE HOLDING LTD.8.22%224 445
PFIZER-9.78%218 630
NOVARTIS3.69%194 472
MERCK AND COMPANY-4.21%189 055